Equities
  • Price (EUR)13.20
  • Today's Change0.24 / 1.85%
  • Shares traded800.00
  • 1 Year change+28.47%
  • Beta0.7455
Data delayed at least 15 minutes, as of Feb 16 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.

  • Revenue in USD (TTM)14.12bn
  • Net income in USD-3.69bn
  • Incorporated2019
  • Employees32.00k
  • Location
    Viatris Inc1000 Mylan BoulevardCANONSBURG 15317United StatesUSA
  • Phone+1 (724) 514-1465
  • Fax+1 (302) 655-5049
  • Websitehttps://www.viatris.com/en
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VTRS:NSQ since
announced
Transaction
value
Aculys Pharma IncDeal completed15 Oct 202515 Oct 2025Deal completed58.81%--
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.